{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:41:33Z","timestamp":1777052493032,"version":"3.51.4"},"reference-count":40,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NCCN-Pfizer-Sumitomo Pharma America Inc."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,3,31]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treatment for high-risk locally advanced prostate cancer typically includes radiation or radical prostatectomy plus androgen deprivation therapy (ADT), but the optimal use of neoadjuvant and adjuvant ADT in practice remains unclear. Relugolix and enzalutamide have demonstrated strong efficacy independently in the setting of advanced disease, but their combined use in neoadjuvant\/adjuvant therapy has not been studied. This trial investigates their safety and efficacy as neoadjuvant\/adjuvant therapy in patients undergoing definitive local treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Relugolix and Enzalutamide as Neoadjuvant\/Adjuvant to Local-regional treatment in Patients with High-risk, Locally Advanced Prostate Cancer (RENAPCA) is a prospective, single-arm, open-label phase Ib trial with blinded outcome assessment. The study is conducted across four tertiary oncology centres within the United States. Eligible participants are adult men with pathologically confirmed locally advanced high-risk prostate cancer who are candidates for definitive local therapy. Patients with significant comorbidities or a life expectancy of less than 6 months are excluded. The trial includes a 3+3 dose-escalation safety lead-in cohort (up to 12 patients) to determine dose-limiting toxicities and recommended phase 2 dose, followed by a dose expansion cohort (up to 46 patients). Interventions consist of 6\u2009months of neoadjuvant therapy with relugolix plus enzalutamide, definitive local therapy (radical prostatectomy or radiation therapy), and 18 months of adjuvant therapy with relugolix plus enzalutamide. Primary outcomes include pathologic CR rate and minimal residual disease rate. Secondary outcomes include prostate-specific antigen response, progression-free survival, objective response rate, frequency and severity of adverse events, and positive margin\/pathologic downgrade rate. Exploratory objectives include patient-reported outcomes and quality of life measures. RENAPCA will assess the safety and efficacy of neoadjuvant\/adjuvant relugolix+enzalutamide in high-risk, locally advanced prostate cancer to support future larger-scale studies and potentially improve treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This research protocol has been approved by the Institutional Review Board of the University of Oklahoma Health Sciences Center (7 March 2024). The study is based on voluntary participation with informed written consent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06130995\">NCT06130995<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-112623","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:05:33Z","timestamp":1777050333000},"page":"e112623","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant\/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06130995","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06130995","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06130995","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8302-1312","authenticated-orcid":false,"given":"Matthew","family":"Loper","sequence":"first","affiliation":[{"name":"College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Qadar","sequence":"additional","affiliation":[{"name":"The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara K.","family":"Vesely","sequence":"additional","affiliation":[{"name":"The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Gunter","sequence":"additional","affiliation":[{"name":"The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adanma","family":"Ayanambakkam","sequence":"additional","affiliation":[{"name":"The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuejin","family":"Wen","sequence":"additional","affiliation":[{"name":"The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cookson","sequence":"additional","affiliation":[{"name":"The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Stratton","sequence":"additional","affiliation":[{"name":"The Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"2026042410051734000_16.4.e112623.1","unstructured":"American Cancer Society . Key statistics for prostate cancer. 2025. Available: https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/about\/key-statistics.html [Accessed 20 Apr 2025]."},{"key":"2026042410051734000_16.4.e112623.2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/jamaoncol.2018.4836","article-title":"Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality","volume":"5","author":"Tilki","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026042410051734000_16.4.e112623.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.7510"},{"key":"2026042410051734000_16.4.e112623.4","first-page":"293","article-title":"Studies on prostatic cancer: I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"2026042410051734000_16.4.e112623.5","first-page":"S3","article-title":"Androgen deprivation therapy in the treatment of advanced prostate cancer","volume":"9 Suppl 1","author":"Perlmutter","year":"2007","journal-title":"Rev Urol"},{"key":"2026042410051734000_16.4.e112623.6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.5011"},{"key":"2026042410051734000_16.4.e112623.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70560-0"},{"key":"2026042410051734000_16.4.e112623.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"2026042410051734000_16.4.e112623.9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.21037\/tau.2018.01.06","article-title":"Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy","volume":"7","author":"Siddiqui","year":"2018","journal-title":"Transl Androl Urol"},{"key":"2026042410051734000_16.4.e112623.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70223-0"},{"key":"2026042410051734000_16.4.e112623.11","first-page":"45","article-title":"Adjuvant therapy in high-risk prostate cancer","volume":"17","author":"Shevach","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"2026042410051734000_16.4.e112623.12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01777"},{"key":"2026042410051734000_16.4.e112623.13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","article-title":"The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant\/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial","volume":"78","author":"Dearnaley","year":"2020","journal-title":"Eur Urol"},{"key":"2026042410051734000_16.4.e112623.14","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001702"},{"key":"2026042410051734000_16.4.e112623.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1357"},{"key":"2026042410051734000_16.4.e112623.16","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1200\/JCO.18.00606","article-title":"Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association\/American Society for Radiation Oncology\/Society of Urologic Oncology Guideline","volume":"36","author":"Bekelman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026042410051734000_16.4.e112623.17","unstructured":"National Comprehensive Cancer Network (NCCN) . NCCN clinical practice guidelines in oncology. 2023. Available: https:\/\/www.nccn.org\/professionals\/physician_gls"},{"key":"2026042410051734000_16.4.e112623.18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JU.0000000000002854","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline","volume":"208","author":"Eastham","year":"2022","journal-title":"Journal of Urology"},{"key":"2026042410051734000_16.4.e112623.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70700-8"},{"key":"2026042410051734000_16.4.e112623.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02438"},{"key":"2026042410051734000_16.4.e112623.21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clgc.2013.11.009","article-title":"Preoperative androgen deprivation therapy for localized prostate cancer: delayed biochemical recurrence in high-risk disease","volume":"12","author":"Pal","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"2026042410051734000_16.4.e112623.22","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1210\/jc.2015-2770","article-title":"Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males","volume":"100","author":"MacLean","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026042410051734000_16.4.e112623.23","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1002\/cam4.2442","article-title":"Phase I trial of TAK-385 in hormone treatment-na\u00efve Japanese patients with nonmetastatic prostate cancer","volume":"8","author":"Suzuki","year":"2019","journal-title":"Cancer Med"},{"key":"2026042410051734000_16.4.e112623.24","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"2026042410051734000_16.4.e112623.25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/OP.21.00206","article-title":"Recent Advances in the Management of Metastatic Prostate Cancer","volume":"18","author":"Sayegh","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2026042410051734000_16.4.e112623.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800536"},{"key":"2026042410051734000_16.4.e112623.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2344"},{"key":"2026042410051734000_16.4.e112623.28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5100","article-title":"PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)","volume":"37","author":"Taplin","year":"2019","journal-title":"JCO"},{"key":"2026042410051734000_16.4.e112623.29","doi-asserted-by":"crossref","first-page":"864646","DOI":"10.3389\/fruro.2022.864646","article-title":"Neoadjuvant Systemic Therapy Prior to Radical Prostatectomy for Clinically Localized High-Risk Prostate Cancer","volume":"2","author":"Perera","year":"2022","journal-title":"Front Urol"},{"key":"2026042410051734000_16.4.e112623.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9881"},{"key":"2026042410051734000_16.4.e112623.31","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0165"},{"key":"2026042410051734000_16.4.e112623.32","first-page":"267","article-title":"New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen","volume":"5","author":"Labrie","year":"1982","journal-title":"Clin Invest Med"},{"key":"2026042410051734000_16.4.e112623.33","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"2026042410051734000_16.4.e112623.34","unstructured":"National Institutes of Health . Label: xtandi- enzalutamide capsule XTANDI- enzalutamide tablet. U.S. National Library of Medicine; 2025. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf"},{"key":"2026042410051734000_16.4.e112623.35","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1200\/JCO.2023.41.16_suppl.5051","article-title":"The effect of a reduced dose of enzalutamide on fatigue and cognition","volume":"41","author":"Overbeek","year":"2023","journal-title":"JCO"},{"key":"2026042410051734000_16.4.e112623.36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2024.42.4_suppl.102","article-title":"A study of the association between enzalutamide blood concentrations and adverse events in patients with castration-resistant prostate cancer","volume":"42","author":"Iguchi","year":"2024","journal-title":"JCO"},{"key":"2026042410051734000_16.4.e112623.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2026042410051734000_16.4.e112623.38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2026042410051734000_16.4.e112623.39","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221141306","article-title":"Optimal assessment of quality of life for patients with prostate cancer","volume":"14","author":"Briggs","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2026042410051734000_16.4.e112623.40","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-112623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:05:38Z","timestamp":1777050338000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-112623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,24]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjopen-2025-112623"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-112623","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}